Clinical Study on Lot-to-lot Consistency and Immune Persistence of Three Commercial Batches of PPSV23

Phase 3 Active not recruiting 990 enrolled Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd

RandomizedParallel-groupQuadruple-blindPrevention

Summary

The research objective is to evaluate lot-to-lot consistency and immune persistence of three commercial batches of 23 valent pneumococcal polysaccharide vaccine.

Timeline

Start: 2023-01-30
Primary completion: 2024-12-30
Completion: 2028-06-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Pneumovax 23	Vaccine	0.5 ml	Intramuscular

Indications

No indication recorded.